STOCK TITAN

Lexeo LX2020: 80% mean drop in brief rapid-heartbeat burden

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) reported interim Phase I/II results for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy. In seven high-dose participants, latest assessments showed mean reductions from baseline of 80% in NSVT burden and 44% in PVC burden; six of seven improved on NSVT and five of seven on PVC burden.

Across 10 participants, Lexeo reported no clinically significant complement activation or study discontinuations. One previously disclosed Grade 3 serious adverse event of ventricular tachycardia occurred three months after dosing and was treated with anti-arrhythmic medication. Lexeo said the FDA is open to guideline-defined NSVT as a primary surrogate endpoint for potential accelerated approval; final study design, statistical analysis plan and confirmatory strategy are expected in the first half of 2027, and pivotal-study initiation is expected in the second half of 2027.

At September 30, 2026, cash, cash equivalents and investments were $219.1 million, which Lexeo expects to fund operations into 2028. Q3 net loss was $38.3 million versus $20.3 million a year earlier; R&D expense was $34.5 million versus $15.7 million, with most of the increase attributed to one-time costs including the Mantle Therapeutics acquisition and an LX2006 development milestone.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • Minor pointHigh-dose cohort: 80% mean NSVT reduction at latest assessment.

Negative

  • Major pointQ3 net loss: $38.3 million, versus $20.3 million in Q3 2025.

Filing Explained

Lexeo announced Toby Schilke’s appointment as an independent director to its Board, a disclosed change in Board membership.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Mean NSVT burden reduction 80% Latest assessment relative to baseline in high-dose cohorts (n=7).
Mean PVC burden reduction 44% Latest assessment relative to baseline in high-dose cohorts (n=7).
Trial participants dosed 10 participants HEROIC-PKP2 Phase I/II trial; data cutoff October 15, 2026.
Cash, cash equivalents and investments $219.1 million As of September 30, 2026; Lexeo expects this to fund operations into 2028.
Research and development expense $34.5 million Three months ended September 30, 2026, compared with $15.7 million in 2025.
General and administrative expense $5.9 million Three months ended September 30, 2026, compared with $6.0 million in 2025.
Net loss $38.3 million Three months ended September 30, 2026, compared with $20.3 million in 2025.
Net loss per share $0.43 per share Basic and diluted, three months ended September 30, 2026; $0.33 per share in 2025.
non-sustained ventricular tachycardia (NSVT) medical
"reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT)"
premature ventricular contractions (PVC) medical
"reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC)"
primary surrogate endpoint regulatory
"guideline-defined NSVT as a primary surrogate endpoint"
accelerated approval regulatory
"to support potential accelerated approval of LX2020"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
complement activation medical
"No clinically significant complement activation was observed"
Complement activation is a chain reaction in the immune system where proteins rapidly tag and help remove microbes, damaged cells or foreign substances; imagine a row of falling dominos that amplifies an immune response. For investors, it matters because unwanted activation can cause inflammation, tissue damage or infusion reactions tied to drug safety, while controlled activation is a target mechanism for therapies and a potential biomarker for regulatory decisions and commercial value.
adeno-associated viral capsid technical
"within an adeno-associated viral capsid, AAVrh10"
Research and development expense $34.5 million Compared with $15.7 million in the three months ended September 30, 2025.
General and administrative expense $5.9 million Compared with $6.0 million in the three months ended September 30, 2025.
Net loss $38.3 million Compared with $20.3 million in the three months ended September 30, 2025.
Net loss per common share, basic and diluted $0.43 per share Compared with $0.33 per share in the three months ended September 30, 2025.
Guidance

As of September 30, 2026, cash, cash equivalents and investments were $219.1 million, which Lexeo believes will fund operations into 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What interim LXEO LX2020 results were reported?

Lexeo reported mean reductions from baseline of 80% in NSVT burden and 44% in PVC burden at latest assessment among seven high-dose participants; six of seven improved on NSVT and five of seven on PVC burden.

What did the FDA say about LXEO’s LX2020 pivotal study?

Lexeo said the FDA is open to guideline-defined NSVT as a primary surrogate endpoint to support potential accelerated approval. Final study design, statistical analysis plan and confirmatory strategy are expected in the first half of 2027, and Lexeo expects to initiate the pivotal study in the second half of 2027.

What were Lexeo’s Q3 2026 financial results?

For the three months ended September 30, 2026, Lexeo reported a $38.3 million net loss, or $0.43 per share, compared with a $20.3 million net loss, or $0.33 per share, in 2025. Cash, cash equivalents and investments were $219.1 million as of September 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000190710800019071082026-11-162026-11-16

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

Lexeo Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-41855

85-4012572

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

345 Park Avenue South, Floor 6

 

New York, New York

 

10010

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 212 547-9879

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

LXEO

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


Item 2.02 Results of Operations and Financial Condition.

 

On November 16, 2026, Lexeo Therapeutics, Inc. (the “Company”) issued a press release announcing business highlights and its financial results for the three and nine months ended September 30, 2026. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

 

Item 7.01 Regulation FD Disclosure.

The corporate presentation to be used in connection with the webcast described in Item 8.01 below is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01 Other Events.

In the press release described in Item 2.02 above, the Company announced positive interim Phase I/II clinical data and regulatory updates for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (“PKP2-ACM”). As part of the press release, the Company announced that it would be hosting a conference call and webcast at 8:00 a.m. ET on November 16, 2026 to discuss the interim Phase I/II clinical data of LX2020 for the treatment of PKP2-ACM.

 

Also on November 16, 2026, the Company posted on its website an updated corporate presentation (the “Corporate Presentation”). The Corporate Presentation will be used from time to time in meetings with investors and analysts. A copy of the Corporate Presentation is attached hereto as Exhibit 99.3 and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

Number

Description

99.1

 

Press release issued by the Company on November 16, 2026, furnished herewith

99.2

 

Corporate Presentation (LX2020), dated November 16, 2026, furnished herewith

99.3

 

Corporate Presentation, dated November 16, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Lexeo Therapeutics, Inc.

 

 

 

 

Date:

November 16, 2026

By:

/s/ R. Nolan Townsend

 

 

 

 R. Nolan Townsend, Chief Executive Officer

 


Exhibit 99.1

img46940271_0.jpg

 

Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results

 

Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and

44% mean reduction in premature ventricular contractions at latest assessment

 

LX2020 generally well tolerated across 10 participants with no clinically significant complement activation

 

U.S. Food and Drug Administration open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint to support potential accelerated approval of LX2020

 

Cash, cash equivalents and investments of $219.1 million expected to provide operational runway into 2028

 

Company to host webcast today at 8:00 AM ET

 

NEW YORK – November 16, 2026 (GLOBE NEWSWIRE) – Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced positive interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including non-sustained ventricular tachycardia (NSVT) and premature ventricular contractions (PVC), as well as improvement in measures of right ventricular function and patient-reported symptoms. Lexeo is now designing a pivotal study with NSVT as a primary surrogate endpoint to support potential accelerated approval. The final study design including the statistical analysis plan and confirmatory strategy remains subject to future discussions with the FDA.

 

“These data further strengthen our confidence in LX2020 and its potential to address the underlying biology of PKP2-ACM,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “The magnitude and consistency of NSVT reduction far exceed what available therapies have historically achieved, underscoring how LX2020 could meaningfully improve outcomes for individuals with PKP2-ACM. Our regulatory discussions also provide important clarity on the path forward, including the FDA’s openness to the use of NSVT as a primary endpoint in a planned pivotal study given the well-established association between NSVT and sustained, life-threatening arrhythmic risk.”

 

“For families living with PKP2 arrhythmogenic cardiomyopathy, the risks and uncertainties reach far beyond the clinic and into every part of daily life,” said Walker Frahm, Chief Executive Officer of the Foundation for Inherited Arrhythmias (FIA). “Our community has waited a long time for treatments that might address the underlying cause of this disease. Early results like these give ACM families reason to hope for better, more targeted care. We look forward to larger studies that build on these findings.”

 

LX2020 Interim Update

Ten participants have been dosed in the HEROIC-PKP2 Phase I/II clinical trial, including three participants in Cohort 1 at the low dose (2×1013 vg/kg) and seven participants in Cohorts 2 and 3 at the high dose (6×1013vg/kg). As of the October 15, 2026 data cutoff date, nine of ten participants reached at least 12 months of follow-up, with the remaining participant reaching nine months of follow-up. Safety and efficacy data are summarized for all ten participants at latest assessment.

 

1


Clinical Data

•
80% mean reduction in NSVT at latest assessment relative to baseline in high-dose cohorts (n=7), with deepening reduction in mean NSVT burden over time; six of seven participants demonstrated improvement at latest assessment
•
44% mean reduction in PVC burden at latest assessment relative to baseline in high-dose cohorts (n=7); five of seven participants demonstrated improvement at latest assessment
•
Five of seven participants in high-dose cohorts reported symptom improvement at latest visit relative to baseline on the Patient Global Impression of Change (PGIC) scale, a patient-reported outcome measure
•
Preliminary evidence of stabilization or improvement in cardiac function assessed by cardiac MRI in the majority of participants in high-dose cohorts

· Cardiac biopsy findings demonstrated dose-dependent increases in LX2020 transduction, mean exogenous PKP2 mRNA expression and mean PKP2 protein expression

 

Safety

•
LX2020 generally well tolerated across ten participants dosed
•
No clinically significant complement activation was observed and no participant discontinued the study
•
Previously disclosed elevations in liver function tests (LFT) were observed in the high-dose cohorts and were treated successfully per the trial protocol with no complications or hospitalizations
•
One previously disclosed Grade 3 serious adverse event of ventricular tachycardia (VT) was observed three months after dosing. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required

 

Regulatory Update and Next Steps

•
The FDA is open to use of guideline-defined NSVT as a primary surrogate endpoint in an accelerated approval pivotal study
•
Finalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027
•
Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027

 

Q3 2026 Earnings Update

Today, Lexeo also reported financial results for the third quarter of 2026:

•
Cash Position: As of September 30, 2026, cash, cash equivalents, and investments in marketable securities were $219.1 million, which Lexeo believes will be sufficient to fund operations into 2028
•
Research & Development Expenses: Research and Development expenses were $34.5 million for the three months ended September 30, 2026, compared to $15.7 million for the three months ended September 30, 2025. The majority of the increase was driven by one-time costs including the acquisition of Mantle Therapeutics, which closed in September 2026, as well as a development milestone that was achieved in the third quarter of 2026 related to LX2006 pivotal study initiation
•
General & Administrative Expenses: General and Administrative expenses were $5.9 million for the three months ended September 30, 2026, compared to $6.0 million for the three months ended September 30, 2025
•
Net Loss: Net loss was $38.3 million or $0.43 per share (basic and diluted) for the three months ended September 30, 2026, compared to $20.3 million or $0.33 per share (basic and diluted) for the three months ended September 30, 2025

 

Lexeo also announced the appointment of Toby Schilke as an independent director to the Board of Directors. Most recently, Mr. Schilke served as Chief Financial Officer of Crinetics Pharmaceuticals. He previously served as Chief Financial Officer at Revance Therapeutics and Achaogen. Earlier in his career, he held leadership roles across corporate development, commercial finance, marketing, and global operations at Roche and Genentech.

 

2


Corporate Webcast Details
Lexeo Therapeutics will host a webcast at 8:00 AM ET today, November 16, 2026. Analysts and investors can participate by accessing the webcast live on the
News & Events page in the Investors section of Lexeo’s website, www.lexeotx.com. The webcast will be archived on the company’s website following the call.

 

About LX2020

LX2020 is an AAV-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM). Mutations in the PKP2 gene are the most common genetic cause of ACM, responsible for approximately 50% of cases and estimated to affect approximately 60,000 people in the United States. PKP2 deficiency in ACM can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities, and sudden cardiac death. LX2020 is designed to systemically deliver a functional, full-length PKP2 gene within an adeno-associated viral capsid, AAVrh10, to cardiomyocytes to restore the desmosomal complex and cell-to-cell adhesion. LX2020 is being evaluated in the single-arm, open-label, multi-center HEROIC-PKP2 Phase I/II clinical trial (NCT06109181). LX2020 has been granted Regenerative Medicine Advanced Therapy, Orphan Drug and Fast Track designations by the FDA.

 

About Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need.

 

Cautionary Note Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs and the anticipated benefits of its current product candidates, the timing and likelihood of

potential regulatory developments, trial design changes and approval, and expectations regarding the time period

over which Lexeo’s capital resources will be sufficient to fund its anticipated operations and estimates regarding

Lexeo’s financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs, including the outcome of ongoing

discussions with the FDA regarding the design of the pivotal study to support an application for accelerated approval of LX2020, statistical analysis plan and confirmatory evidence strategy; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

 

Media Response:

Media@lexeotx.com

 

Investor Response:

Investors@lexeotx.com

3


Lexeo Therapeutics, Inc.

Selected Financial Information

(Unaudited, in thousands, except share and per share amounts)

 

Statements of Operations

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

Research and development

$

34,496

 

 

$

15,695

 

 

$

69,226

 

 

$

47,587

 

General and administrative

 

5,903

 

 

 

5,953

 

 

 

21,526

 

 

 

38,554

 

Total operating expenses

 

40,399

 

 

 

21,648

 

 

 

90,752

 

 

 

86,141

 

Operating loss

 

(40,399

)

 

 

(21,648

)

 

 

(90,752

)

 

 

(86,141

)

Other income and expense

 

 

 

 

 

 

 

 

 

 

 

Gain on long-term investment

 

-

 

 

 

-

 

 

 

-

 

 

 

3,390

 

Other expense, net

 

(9

)

 

 

(9

)

 

 

(16

)

 

 

(27

)

Interest expense

 

(12

)

 

 

(22

)

 

 

(43

)

 

 

(75

)

Interest income

 

2,160

 

 

 

1,456

 

 

 

6,467

 

 

 

3,917

 

Amortization of premium on investments in U.S. Treasury securities, net

 

(40

)

 

 

(60

)

 

 

(19)

 

 

 

(106

)

Total other income and expense

 

2,099

 

 

 

1,365

 

 

 

6,389

 

 

 

7,099

 

Loss from operations before income taxes

 

(38,300

)

 

 

(20,283

)

 

 

(84,363

)

 

 

(79,042

)

Income taxes

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

$

(38,300

)

 

$

(20,283

)

 

$

(84,363

)

 

$

(79,042

)

Net loss per common share, basic and diluted

$

(0.43

)

 

$

(0.33

)

 

$

(0.99

)

 

$

(1.72

)

Weighted average number of shares outstanding used in computation of net loss per common share, basic and diluted

 

88,681,360

 

 

 

60,980,867

 

 

 

85,191,438

 

 

 

45,991,572

 

 

 

 

Balance Sheet Data

 

 

 

September 30,

 

December 31,

 

2026

 

2025

Cash, cash equivalents, and investments in U.S. Treasury securities

 

 $ 219,134

 

 $ 246,568

Total assets

 

                   243,916

 

                   268,688

Total liabilities

 

                     27,225

 

                     22,019

Total stockholders' equity

 

                  216,691

 

                   246,669

 

 

4


Slide 1

Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 in PKP2 Arrhythmogenic Cardiomyopathy November 16, 2026 Exhibit 99.2 1


Slide 2

Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, and the timing and likelihood of potential regulatory developments, trial design changes and approval. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs, including the outcome of ongoing discussions with the FDA regarding the design of the pivotal study to support an application for accelerated approval of LX2020, statistical analysis plan and confirmatory evidence strategy; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Forward-looking statements


Slide 3

CLINICAL EFFICACY 80% mean reduction in NSVT and 44% mean reduction in PVC burden at latest assessment in participants in high-dose cohorts (n=7) Deepening reduction in mean NSVT burden over time in high-dose cohorts 5 of 7 participants in high-dose cohorts reported symptom improvement on PGIC scale at latest visit Preliminary evidence of stabilization or improvement in cardiac function on cardiac MRI in majority of participants in high-dose cohorts SAFETY REGULATORY PATH LX2020 generally well tolerated across 10 participants dosed No clinically significant complement activation and no study discontinuations FDA open to guideline-defined NSVT1,2 as a primary surrogate endpoint to support potential accelerated approval of LX2020 Finalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027 Lexeo expects to initiate pivotal study under accelerated approval pathway in 2H 2027 Interim LX2020 data demonstrate clinically meaningful reductions in severe arrhythmia burden 1 2 3 NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular contractions; PGIC, Patient Global Impression of Change. Sources: (1) Al-Khatib SM, et al. Circulation. 2018;138:e272–e391. (2) Carrick RT, et al. Circ Arrhythm Electrophysiol. 2022;15:e011207. NSVT defined in guidelines as hemodynamically stable ventricular tachycardia at a rate of >100 beats per minute, lasting three or more beats and less than 30 seconds.


Slide 4

Significant commercial potential for LX2020 given unmet need and global patient population 60K Patients in the U.S. >$4-6B Total addressable market opportunity Larger-rare, diagnosed population Significant commercial upside at peak Trial ready Broad patient pool expected to support rapid recruitment Manufacturing scale Differentiated Lexeo process will enable rapid and cost-efficient supply Global prevalence Pivotal study feasible across US, EU, Asia and other geographies


Slide 5

Treatment response in PKP2-ACM may be reflected across complementary measures of disease activity ACM, arrhythmogenic cardiomyopathy; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; VA, ventricular arrhythmia; ICD, implantable cardioverter defibrillator; RVEF, right ventricular ejection fraction; AAD, anti-arrhythmia drug. Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (2) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385; (3) Elias Neto J, et al. Arq Bras Cardiol. 2019;112(1):91-103; (4) Wang W, et al. Europace. 2019;21(1):9-21. Measurements of arrhythmia and function have been assessed within individuals and across ACM populations Patient-reported outcomes Treatment escalation (changes in AADs, ablation, transplant) Patient & clinical burden Despite currently available treatment options, patients continue to experience significant negative impact on quality of life PVC burden NSVT burden Sustained VA / ICD shocks Arrhythmic activity Duration, frequency and proportion of patients experiencing events are evaluable parameters Right ventricular ejection fraction (RVEF) RV size and volumes Myocardial strain / contractility Myocardial structure & function Improvements in muscle strain may precede RV functional improvements due to existing scar tissue ACM / ARVC heart


Slide 6

Ventricular arrhythmic activity exists along a spectrum of increasing complexity and clinical consequence Non-sustained Ventricular Tachycardia (NSVT) Three or more consecutive ventricular beats lasting < 30 seconds at a ventricular rate of > 100 bpm1 Indicates increased ventricular electrical instability and a higher risk of sustained arrhythmias, particularly in structural heart disease such as ACM Sustained Ventricular Tachycardia (VT) Continuous ventricular tachycardia either lasting ≥ 30 seconds or requiring intervention to terminate Associated with significantly greater risk of hemodynamic compromise, degeneration to ventricular fibrillation, and sudden death Serious Clinical Outcomes If sustained VT persists, an implantable cardioverter-defibrillator (ICD) can detect the arrhythmia and deliver a shock to restore a normal heart rhythm. If sustained VT degenerates into ventricular fibrillation (VF) or is not terminated, it can lead to sudden cardiac death. Increasing Arrhythmic Risk Isolated PVC NSVT Sustained VT ICD Firing / SCD Premature Ventricular Contractions (PVCs) Early ventricular beats that occur before the next expected heartbeat Common in the general population In structural heart disease (e.g., ACM), PVCs are more frequent ICD Firing Sudden Cardiac Death (SCD) Arrhythmia Burden Sustained VT (does not self-terminate) Run of NSVT (terminates spontaneously) Isolated PVC Sources: (1) Al-Khatib SM, et al. Circulation. 2018;138(13):e272-e391. NSVT defined in guidelines as hemodynamically stable ventricular tachycardia at a rate of >100 beats per minute, lasting three or more beats and less than 30 seconds.


Slide 7

NSVT history and incidence is high among ACM patients with ICDs Arrhythmia Burden NSVT-ASSOCIATED ICD IMPLANTATION NSVT IS AN ESTABLISHED THRESHOLD FOR ICD DECISIONS ~1.7x higher rate of ICD implantation in patients with a history of NSVT1 NSVT is a clinically relevant marker included in major ACM risk models2, with ≥1 NSVT per day as an established threshold to predict future sustained and life-threatening VA3. NSVT history is a major risk factor supporting ICD implantation4 NSVT is an established criteria for ICD intervention ~75% of ACM patients have ICDs5 Most ACM patients have ICDs ICDs remain standard of care for most ACM patients, for both primary and secondary prevention4 ICD HISTORY ENRICHES FOR AN IDENTIFIABLE POPULATION 80-100% of patients in SNAPSHOT (n=15) and HEROIC (n=10) studies respectively had NSVT burden at baseline Holter Inclusion criteria that specify ICD implantation and a minimum daily threshold of PVCs select for a trial population with clinically meaningful, measurable NSVT burden ICD eligibility criteria may select more patients with underlying NSVT NSVT, non-sustained ventricular tachycardia; ACM, arrhythmogenic cardiomyopathy; ICD, implantable cardioverter defibrillator; VA, ventricular arrhythmia; PVC, premature ventricular contraction. Sources: (1) Carrick RT, et al. Euro Heart Journal. 2024;45:538-548. (2) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (3) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385. (4) Corrado D, et al. Circulation. 2015;132(5):441-453, (5) Bosman LP, et al. Europace. 2021;00:1-10.


Slide 8

Ejection fraction and RV free wall strain provide complementary views of systolic function in ACM Ejection fraction (EF) Pump output Percentage of ventricular blood volume ejected with each contraction of the RV or LV Global measure of systolic function EF may remain stable in early ACM LVEF largely preserved in those with early-stage ACM1 RV dysfunction often precedes overt LV dysfunction during ACM progression associated with increased severe ventricular arrhythmic risk in ACM2 RV free wall strain Muscle function Percentage shortening of the RV free wall muscle during systolic contraction More sensitive marker of function RV strain changes earlier and faster Abnormal RV Free Wall Strain MEASUREMENT PROGRESSION IN ACM OUTCOMES RV strain abnormalities emerge before RVEF shows any deterioration1 In those with early-stage ACM, RV free wall strain worsened by ~0.6% points per year on average represents more advanced stage of ACM, associated with increased risk of cardiac death and transplantation3,4 Increased structural progression risk5 with abnormal strain > -20% Increased VA risk6 with abnormal strain > −17% Lower RVEF Lower LVEF LVEF (%) Follow up (years) Age 30-50 years 40 50 60 0 5 10 15 P = 0.835 RVfwLS (%) Follow up (years) Age 30-50 years -20 -15 -10 0 5 10 15 P < 0.001 -25 VA-free survival Time (years) 1.00 0.75 0.50 0.25 0.00 0 2 6 10 4 8 >-17 -17 to -24 <-24 Cardiac Function RV, right ventricular; ACM, arrhythmogenic cardiomyopathy; LV, left ventricular; RVEF, right ventricular ejection fraction; LVEF, left ventricular ejection fraction; VA, ventricular arrhythmia. Sources: (1) Kirkels FP, et al. J Am Coll Cardiol. 2023;82(9):785-797. (2) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (3) Corrado D, et al. Heart. 2022;108(9):733-742. (4) Luo Y, et al. ESC Heart Fail. 2023;10(5):3028-3037. (5) Malik N, et al. J Am Heart Assoc. 2020;9(7):e015016. (6) Kirkels FP, et al. Eur Heart J Cardiovasc Imaging. 2023;24(12):1710-1718.


Slide 9

LX2020 is being evaluated in an ongoing Phase 1/2 study: HEROIC-PKP2 2 Key Inclusion Criteria Adults (18-65 years) Diagnosis of ACM with documented PKP2 mutation Existing ICD that is MRI compatible Minimum threshold of PVCs/24-hr Neutralizing anti-AAVrh.10 titer cutoff 1 Study Design & Objective Design: 52-week open-label study with a 4-year long term follow up Objective: To assess the safety and efficacy of LX2020 in individuals with PKP2-ACM High dose (n=7): 6.0x1013 vg/kg Low dose (n=3): 2.0x1013 vg/kg 52-Week Fully Enrolled 3 Key Measurements Change in symptoms (NYHA Class and PROs) Ventricular arrhythmias and associated measures (PVC, NSVT, VT, QRS) Cardiac structure & function (EF, EDV, ESV, RV strain) Vector Transduction & Expression ACM, arrhythmogenic cardiomyopathy; ICD, implantable cardioverter defibrillator; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; RV, right ventricular; NYHA, New York Heart Association; PROs, patient reported outcomes. Note: LX2020 is administered systemically; participants receive immune suppression with prednisone and sirolimus on the day prior to treatment through ~14 weeks following LX2020 dosing.


Slide 10

Baseline characteristics consistent with PKP2-ACM, with more severe arrhythmia burden in high-dose cohorts Cohort 1 (2.0x1013 vg/kg) Cohorts 2 & 3 (6.0x1013 vg/kg) Participant 1 2 3 4 5 6 7 84 9 10 Age, years 34 22 29 44 43 30 41 41 28 39 Age at diagnosis 27 21 28 29 28 27 30 34 16 37 Gender M M M M F F F F M M PVC per 24h1 1068 2849 2630 4780 3329 4826 4384 6308 773 5524 NSVT per 7 days1 1 3 2 31 8 13 24 1 5 8 T-wave inversion 5 0 2 3 3 3 3 3 4 0 QRS duration, ms 124 84 112 90 90 68 90 94 110 106 RVEF (%)2 43 52 42 31 34 33 42 52 43 47 NYHA class I I II I I I I I I I Follow-up, months2 24 18 123 18 18 12 12 12 12 9 Relevant medical history prior to study Sustained VT, ICD shock, ablation Sustained VT, syncope, ICD shock Sustained VT, syncope Sustained VT, VT storm, ICD shock, ablation Sustained VT, ICD shock Sustained VT, near syncope Sustained VT, syncope, ablation, stable use of flecainide at study start Sustained VT, VT storm, ICD shock, ablation Sustained VT, syncope ACM, arrhythmogenic cardiomyopathy; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; RVEF, right ventricular ejection fraction; NYHA, New York Heart Association; VT, ventricular tachycardia; ICD, implantable cardioverter defibrillator. (1) NSVT and PVC baselines updated from January 2026 using guideline-defined NSVT criteria. NSVT runs <100bpm reclassified. Minor PVC count corrections also applied. See Oct. 21, 2026 event for details. (2) Cardiac MRI conducted at 6-, 12- and 24-months of follow up but results lag Holter data. RVEF data were collected during 12-month visit, except for participant 1 at 24-months and participants 9 and 10 at 6-months. (3) Participant 3 declined 18-month follow up visit but is expected for 24-month follow up. (4) Participant 8 on flecainide at study start; no other participants taking background anti-arrhythmic drugs (AADs) at study start.


Slide 11

In high-dose cohorts, 80% mean improvement in NSVT and 44% mean improvement in PVCs at latest assessment Cohort Part. # Latest Visit1 (months) ∆ PVC / 24H Baseline → LV ∆ NSVT / 7d Baseline → LV ∆ RVEF %1 Baseline → LV ∆ RV Strain %1 Baseline → LV ∆ PGIC Scale Baseline  LV Low Dose Cohort 1 (2E13 vg/kg) #1 (M) 24 -57% 1068 → 460 -100% 1 → 0 43  40 -22 → -19 3  3 #2 (M) 18 -1% 2849 → 2807 -23% 3 → 2 52  49 -20 → -20 3  1 #3 (M)2 12 +82% 2630 → 4787 +717% 2 → 17 42  41 -20 → -22 3  4 Mean +23% +213% Majority stable 1/3 improved High Dose Cohort 2 & Cohort 3 (6E13 vg/kg) #4 (M) 18 -48% 4780 → 2472 -86% 31 → 4 31  40 -20 → -17 3  2 #5 (F) 18 +74% 3329 → 5801 -25% 8 → 6 34  33 -12 → -16 3  3 #6 (F) 12 -38% 4826 → 2998 -81% 13 → 2 33  36 -16 → -15 3  2 #7 (F)3 12 -83% 4384 → 752 -96% 24 → 1 42  37 -13 → -19 3  3 #8 (F) 12 -50% 6308 → 3171 +228% 1 → 3 52  48 -19 → -22 3  2 #9 (M) 12 +47% 773 → 1138 -76% 5 → 1 43  39 -15 → -19 3  2 #10 (M) 9 -94% 5524 → 341 -100% 8 → 0 47  43 -14 → -19 3  1 Mean -44% -80% Majority stable or improved 5/7 improved Data cutoff October 15, 2026. RVEF and RV strain values are percentages, changes reported are absolute change (percentage points). LV = latest visit. (1) Cardiac MRI conducted at 6-, 12- and 24-months of follow up but results lag Holter data. RVEF data shown were collected during 12-month visit, except for participant 1 at 24-months and participants 9 and 10 at 6-months. RV strain data shown were collected during 12-month visit except for participants 6, 9, and 10 at 6-months. (2) Participant 3 started background anti-arrhythmic therapy during the study period to manage a PVC spike. Participant declined 18-month follow up visit but is expected for 24-month follow up. (3) Participant 7 started background anti-arrhythmic therapy during the study period to manage VT approximately three months after dosing.


Slide 12

n=3 n=7 n=3 n=6 n=2 n=2 n=1 n=7 n=15 n=6 Deepening reduction in NSVT observed, while natural history shows progressively increased arrhythmic burden Mean NSVT Change: NSVT / 7d NSVT / 7d Deepening NSVT reduction over time with 80% mean reduction at latest visit in high-dose cohorts (n=7) In contrast, participants in SNAPSHOT natural history study demonstrated 53% increase in NSVT at 12 months (n=15) Mean NSVT Change: Participant 3 (low dose) declined 18-month follow up visit but is expected for 24-month follow up.


Slide 13

83% of high-dose cohort had less than 1 NSVT per day at 12 months, a clinically relevant threshold for ACM management n=6 n=2 n=7 n=15 % Participants with Significant NSVT Burden (at least 7 NSVT / 7d; High-dose Cohort) ≥7 NSVT / 7d The presence of NSVT is a clinically relevant marker for risk stratification, monitoring, and management, included in major ACM risk models1 ≥1 NSVT per day is a strong predictor of future sustained and life-threatening ventricular arrhythmias2 While the majority of participants in high-dose cohorts exceeded this threshold at baseline, increasing future arrhythmic risk, 5 of 6 participants had fewer than 1 NSVT per day at 12 months In contrast, natural history demonstrated an increase in NSVT burden over one year, despite existing standard of care Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9. (2) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385.


Slide 14

100% of high-dose participants were below the clinically relevant threshold for NSVT (<1/day) at latest Holter NSVT Change: NSVT / 7d Baseline 6 Mo (n=7) 9 Mo (n=7) 12 Mo (n=6) 18 Mo (n=2) Mean change from baseline - +5% -31% -56% -59% Participants below 1 NSVT/day (<7/7d) 2/7 29% 5/7 71% 4/7 57% 5/6 83% 2/2 100% Mean change from baseline - - - +53% ≥1 NSVT per day is a strong predictor of future sustained VT risk1 All high-dose participants below the clinically relevant threshold for NSVT management at latest visit; 83% responder rate at 12 months NSVT improved in 6/7 participants at latest visit relative to baseline In most participants, NSVT reductions were substantial, greater than the relative risk reduction expected from standard of care HEROIC SNAPSHOT NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia. Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9.


Slide 15

n=3 n=7 n=6 n=2 n=1 n=2 n=3 n=7 n=6 n=15 LX2020 reduced mean PVC burden by 44% in high-dose cohorts at latest assessment Mean PVC Change: Mean PVC Change: PVC / 24h PVC / 24h Mean PVC count decreased 44% at latest assessment across participants in high-dose cohorts (n=7) In contrast, participants in SNAPSHOT natural history study demonstrated a 14% decrease in PVCs at 12 months (n=15) PVC reductions were observed alongside substantial and deepening reductions in NSVT PVC burden and NSVT provide complementary measures of arrhythmic disease activity; greater variability in PVC measurements is well recognized and may reflect the influence of physical activity and other external factors1,2,3 Sources: (1) Cadrin-Tourigny J, et al. Eur Heart J. 2022;43(32):e1-e9; (2) Towbin JA, et al. Heart Rhythm. 2019;16(11):e301-e372. (3) 1) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385. Participant 3 (low dose) declined 18-month follow up visit but is expected for 24-month follow up.


Slide 16

Evidence of improved systolic function with RV free wall strain improvements and EF stabilization n=3 n=7 n=4 n=3 Improvement Mean RV Wall Strain: RV Wall Strain % RV free wall longitudinal strain, assessed via cardiac MRI, measures the percentage shortening of the RV free wall during systole RV wall strain reflects systolic performance and regional RV muscle function; abnormal or reduced shortening reflects early RV dysfunction1 Mean RV free wall strain improved following gene therapy treatment in high-dose cohorts RVEF and LVEF preserved or improved in the majority of participants at latest visit, potentially indicative of slowed disease progression and improved function Sources: (1) Kirkels FP, et al. J Am Coll Cardiol. 2023;82(9):785-797. Cardiac MRI conducted at 6-, 12- and 24-months of follow up but results lag Holter data. RV strain data shown were collected during 12-month visit except for participants 6, 9, and 10 at 6-months.


Slide 17

Supportive findings from cardiac biopsy and ECG LX2020 not detected in pre-dose VCN or mRNA samples as expected. Participant 3 elected not to undergo a post-treatment biopsy. Participant 1 VCN not performed due to insufficient remaining cardiac biopsy tissue following other analyses. GAPDH normalized. Fibrofatty tissue (characteristic of ACM) may impact biopsy samples. Cardiac biopsy not expected in planned pivotal study. Lab vendor identified an error with respect to Patient 2 in PKP2 expression data, impacting the low dose mean. Previously reported data for Patient 2 was 115% and corrected value is 109%. ECG data shown were collected during latest visit except for participant 5 at 12-months, due to a site submission delay. Wagner GS, et al. J Am Coll Cardiol. 2009. Post-Dose Levels1 Post-Dose Vector Copy Number (VCN)1 Post-Dose Exogenous PKP2 (mRNA)1 PKP2 Change from Baseline (Western Blot)3 T-Wave Inversion5 QRS Duration5 Cardiac Biopsy: Dose-dependent increases in mean VCN, mRNA and western blot ECG: T-wave inversion and QRS duration stable across participants Vector copies / diploid genome Copies / µg nucleic acid ng/µg protein Leads Milliseconds (ms) Upper Limit of Normal6


Slide 18

Safety update: Treatment with LX2020 generally well tolerated to date LX2020 generally well tolerated across 10 participants dosed No clinically significant complement activation No study discontinuations Previously disclosed LFT elevations observed in high-dose cohorts were successfully managed per protocol with no hospitalizations or complications One previously disclosed Grade 3 SAE of sustained ventricular tachycardia (VT) was observed three months after dosing. This event is consistent with the natural course of PKP2-ACM and its known clinical manifestations. The participant was successfully treated with anti-arrhythmic medication and discharged with no additional intervention required


Slide 19

Summary of results and next steps for LX2020 Meaningful Clinical Activity LX2020 continues to demonstrate improvements across multiple measures of disease burden and patient experience Increasing Confidence in Dataset Additional follow-up strengthens the durability, consistency, and overall benefit-risk profile of LX2020 Clear Path Forward Regulatory feedback supports continued advancement of LX2020 toward a potential pivotal study Interim HEROIC-PKP2 data continue to support LX2020's potential as the first disease-modifying therapy for PKP2-ACM 1 2 3


Slide 20

Thank you to the ACM community Individuals and families impacted by genetically mediated cardiovascular diseases are at the center of our mission We are grateful to the participants, caregivers, investigators, advocacy organizations and broader ACM community who contributed to HEROIC-PKP2 We remain committed to advancing research, awareness, diagnosis and treatment for individuals living with PKP2-ACM


Slide 21

Thank you

Slide 1

Lexeo Therapeutics Corporate Overview November 2026 Exhibit 99.3 1


Slide 2

Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Lexeo’s expectations and plans regarding its current product candidates and programs, the anticipated benefits of its current product candidates, the timing for receipt and announcement of data from its clinical trials, the timing and likelihood of potential regulatory developments, trial design changes and approval, and expectations regarding the time period over which Lexeo's capital resources will be sufficient to fund its anticipated operations and estimates regarding Lexeo's financial condition. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Lexeo believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements. These forward-looking statements are based upon current information available to the company as well as certain estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Lexeo’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond the company’s control and subject to change. Actual results could be materially different from those indicated by such forward-looking statements as a result of many factors, including but not limited to: expectations regarding the initiation, progress, and expected results of Lexeo’s preclinical studies, clinical trials and research and development programs, including the outcome of ongoing discussions with the U.S. Food and Drug Administration (FDA) regarding the design of our pivotal trials for accelerated approval pathway and the confirmatory strategy; the unpredictable relationship between preclinical study results and clinical study results; delays in submission of regulatory filings or failure to receive regulatory approval; liquidity and capital resources; and other risks and uncertainties identified in Lexeo’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 12, 2026, and subsequent future filings Lexeo may make with the SEC. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Lexeo claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Lexeo expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Forward-looking statements


Slide 3

Reshaping the path of genetic disease Our vision: To set a new standard in the treatment of genetic diseases with high unmet need, charting the path to patient outcomes once thought out of reach Genetic disease expertise with cardiovascular and neurological focus Proven experience in the clinic Platform designed for safety and scalability 3 Individuals and families impacted by Friedreich ataxia


Slide 4

Pioneering science that fundamentally changes how genetic diseases are treated Genetic disease expertise Leader in developing disease-modifying therapies for inherited diseases with high morbidity and mortality Innovative AAV manufacturing Optimized Sf9 baculovirus manufacturing platform designed to support future commercial scale-up for lead gene therapy assets Strong cardiac foundation Genetic medicine know-how rooted in cardiac science, with proven clinical experience and preclinical disease model expertise Strong financial position Cash runway into 2028, supporting multiple value creating milestones Multimodal therapeutic portfolio Robust pipeline of complementary approaches to address the full complexity of genetic disease


Slide 5

Advancing cardiac and neurological therapies in diseases with high unmet need LX3010 LX2006 LX2020 LX2021 LX2022 LX1001 LX1021 LX1020 ALZHEIMER’S PROGRAMS CARDIAC PROGRAMS FRIEDREICH ATAXIA PROGRAMS PRE-CLINICAL CLINICAL Programs Indication Target Gene Modality Discovery Preclinical Phase I/II Phase II/III Friedreich ataxia cardiomyopathy FXN Gene therapy Friedreich ataxia FXN Small molecule Friedreich ataxia FXN Multiple modalities Friedreich ataxia FXN Multiple modalities Arrhythmogenic cardiomyopathy PKP2 Gene therapy DSP (Desmoplakin) cardiomyopathy GJA1 (encoding for CX43 protein) Gene therapy Hypertrophic cardiomyopathy TNN13 Gene therapy Undisclosed Antisense oligonucleotide Alzheimer’s APOE2+ APOE2+ Gene therapy Alzheimer’s Christchurch Christchurch APOE2+ Gene therapy Alzheimer’s APOE2+ /E4- APOE2+ APOE4- Gene therapy DISCOVERY CANDIDATES PRECLINICAL CANDIDATES DISCOVERY CANDIDATES Lexeo retains global rights across all programs


Slide 6

Gene therapy backbone: Highly differentiated capsid supports Lexeo’s lead cardiac programs 1 - Selvan, N. et al. Poster presented at: ASGCT Annual Meeting; May 16-20, 2023; Los Angeles, CA. 2 - Ballon DJ et al, Human Gene Therapy, 2020. Note: FXN, Frataxin; LCMS, Liquid chromatography mass spectrometry. FXN expression assessed with academic LCMS assay, assay validation in progress for pivotal study. LX2006 FXN data previously reported in April 2025. Cardiac tropism of AAVrh.10 may allow lower doses for cardiac gene therapy AAVrh.10 has been utilized systemically across LX2006 and LX2020 with no clinically significant complement activation. Both LX2006 and LX2020 have been generally well-tolerated to date. Significant evidence of protein expression in clinical data with AAVrh.10 capsid In LX2006 clinical data, an increase in FXN protein was observed in human cardiac biopsies at the high dose of 1.2 × 10¹² vg/kg. This remains a relatively low dose in cardiac gene therapy and showed an important increase from baseline. Increased Frataxin Expression Across All Participants Evaluated at 3-Months Post Treatment – Measured by LCMS (Previously Reported) % increase FXN from baseline 200% 300% 100% 0% Cohort Avg. Inc. (%) Part. 6 Part. 9 29% 187% 22% 35% 151% 120% 198% 23% +0.22 +1.81 ng/mg total prot.: C3 (n=4) 115% C1 (n=1) Cohort 2 (n=3) Cohort 3 (n=4) C1 (n=1) 29% C2 (n=3) 69% Part. 10 +0.40 Part. 11 +0.29 Part. 12 +0.11 Part. 14 +0.91 Part. 15 +0.53 Part. 16 +0.60 Compelling cardiac tropism in preclinical data Observed ~1.5x to 2.0x greater biodistribution in the heart compared to AAV9 in multiple large animal models Observed greater trends of functional improvements in PKP2-murine model compared to AAV9 NHP Biodistribution2 Yucatan Minipig Biodistribution1 Copies/μg DNA 15000 10000 5000 0 AAV9 AAVrh.10 I-124 Vector Levels (% total body) 16% 12% 8% 4% 0% AAV9 AAVrh.10 Distribution to the heart ~1.5x higher with AAVrh.10 than AAV9 Distribution to the heart ~2x higher with AAVrh.10 than AAV9


Slide 7

Gene therapy backbone: Lexeo's optimized Sf9 baculovirus platform combines differentiated manufacturing, attractive economics and demonstrated commercial readiness High yield, strong product quality, and an FDA-endorsed commercial manufacturing process position Lexeo for attractive economics and execution readiness across our pipeline Potentially Transformational COGS Profile Lower Cost Per Dose Fewer Production Runs Fewer Empty Capsids Higher Recovery Higher Yield + Well Defined Starting Materials Differentiated Manufacturing Optimized Sf9 baculovirus platform Improved genomic purity High-quality vector production Higher yield and quality compared to HEK model Fewer empty AAV capsids <25% Higher yields 1.0E15 vg/L Greater downstream recovery >55% LX2006 selected for FDA CDRP program FDA confirmed no additional nonclinical bridging studies required Final commercial manufacturing process cleared for SUNRISE-FA 2 Commercial-scale drug product available immediately for patient dosing Launch Readiness


Slide 8

Lexeo’s two clinical stage gene therapy programs address devastating cardiac diseases FA - Friedreich ataxia; FA-CM - Friedreich ataxia cardiomyopathy; FXN - Frataxin; LVMi - Left ventricular mass index; ACM - arrhythmogenic cardiomyopathy; NSVT - non-sustained ventricular tachycardia; SAP – statistical analysis plan. Potential first disease-modifying gene therapy for FA cardiomyopathy (FA-CM) Only program with clinical trial data in FA-CM, which accounts for death in up to 80% of people with FA Clinical data to date demonstrate an encouraging safety profile and sustained and deepening improvements across both cardiac and neurologic measures of FA Finalized SUNRISE-FA 2 pivotal protocol and SAP for accelerated approval; Study initiated in June 2026 Milestones: Topline data readout expected in 2H 2027 Potential BLA submission under accelerated approval pathway in 1H 2028 Friedreich Ataxia Cardiomyopathy LX2006 LX2020 Potential best-in-class treatment for PKP2-ACM; ~60K people in US with no disease-modifying treatment available Clinical data to date demonstrate a well tolerated safety profile and clinically meaningful reductions in severe arrhythmia burden FDA open to guideline-defined NSVT as a primary surrogate endpoint to support potential accelerated approval of LX2020 Milestones: Finalization of pivotal protocol, SAP and confirmatory evidence strategy expected in 1H 2027 Initiation of pivotal study anticipated in 2H 2027 PKP2 Arrhythmogenic Cardiomyopathy Leveraging gene therapy to address devastating cardiac diseases with no existing disease-modifying treatments Goal:


Slide 9

Friedreich Ataxia Platform Lead Asset: Gene Therapy LX2006 9


Slide 10

Friedreich ataxia is a rare, progressive multisystem disease with significant unmet need 1 - Payne R.M. JACC Basic Transl Sci, 2022;13;7(12):1267-1283. 2 - Indelicato, E., et al. Mov Disord, 2024;39(3), 510–518. Cardiac complications are the leading driver of mortality, while neurological decline drives substantial lifelong disability; a leading FA platform must address both. Neurological Burden Progressive ataxia, impaired coordination and peripheral nervous system involvement can materially reduce independence and quality of life Cardiac Burden Cardiac dysfunction in FA associated with a multitude of symptoms but ultimately presents as cardiac hypertrophy and subsequent heart failure1 Cardiac complications account for up to 80% of deaths in those with FA, with an average life expectancy of 35–40 years1,2 There is no approved treatment specifically for FA cardiomyopathy ~5,000 individuals affected by FA in the U.S.2 ~15,000 individuals affected by FA worldwide2 FA is caused by a loss of function mutation in the FXN gene


Slide 11

Timely, multidisciplinary care is critical to identifying and managing Friedreich ataxia cardiomyopathy (FA-CM) Source: HCP and patient market research. COE, center of excellence. 1 - Norrish G., et al. Friedreich’s ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. 2 - Clinical Management Guidelines for Friedreich Ataxia. Chapter 4. The heart and cardiovascular system in Friedreich ataxia. 2022. 3 - Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1-2):46-49. doi:10.1016/j.jns.2011.05.023. PMID:21652007. 4 - Pousset F, Legrand L, Monin ML, et al. A 22-Year Follow-up Study of Long-term Cardiac Outcome and Predictors of Survival in Friedreich Ataxia. JAMA Neurol. 2015;72(11):1334-1341. doi:10.1001/jamaneurol.2015.1855. PMID:26414159. Cardiac symptoms may be absent or under-recognized even as cardiomyopathy evolves, supporting the need for earlier evaluation and coordinated neurology-cardiology care Primary HCP: Pediatrician Primary HCP: Neurologist + ataxia COE Primary HCP: Neurologist + cardiologist + ataxia COE Cardiac complications drive up to 80% of FA deaths, often by the mid-30s, reinforcing the need for early cardiac evaluation, coordinated follow-up and disease-modifying treatments3,4 Long-term FA-CM management Monitoring frequency varies by CM symptoms and severity Ongoing care requires neurology-cardiology coordination No existing evidence that heart-failure medications prevent cardiac dysfunction or provide cardiac benefit to those with preserved EF2 Guidelines recommend cardiology referral at FA diagnosis EKG, echo and blood biomarkers establish cardiovascular baseline Cardiology workup Referral to pediatric neurologist, followed by ataxia specialists; neurologist manages workup Genetic testing confirms FXN mutation Neurology referral & FA diagnosis Patients may remain in pediatric care during early development Diagnosis is often delayed while symptoms evolve Pediatric evaluation Typical age of onset between 5-15 Most early signs are movement-related Small subset of children (~5%) present with cardiac symptoms years before ataxia1 Early symptom onset


Slide 12

Gene therapy LX2006 has the potential to treat the root cause of FA-CM: significant decrease in frataxin in the heart AAV, Adeno-Associated Virus; CAG, Chicken Beta-Actin; cDNA, Copy DNA; FA, Friedreich Ataxia; FXN, Frataxin; Poly-A, Poly Adenosine. LX2006 construct: AAVrh.10hFXN Ubiquitous promoter FXN cDNA (full length gene) Rabbit β-globin polyA CAG FXN gene Poly-A FA Cardiomyopathy FXN deficiency results in mitochondrial dysfunction and leads to deficient energy production in thickened cardiomyocytes Cardiomyocyte FXN deficiency FXN mutation Mitochondria Iron Cluster LX2006 Mechanism Delivery of FXN gene in cardiomyocytes by LX2006 is intended to increase frataxin protein levels in the mitochondria and improve heart muscle function Cardiomyocyte Functional FXN gene Increased FXN expression Mitochondria FXN with iron LX2006 Friedreich Ataxia


Slide 13

Elevated LVMi predicts mortality in FA and is not expected to decrease significantly without intervention HR, Hazard Ratio; CI, Confidence Internal; LVMi, Left Ventricular Mass Index. Note: 10g/m2 represents approximately 10% change in LVMi based on echocardiography measurements of upper bound of normal (105 g/m2). 1 - Pousset, F. et al. JAMA Neurol, 2015;72(11):1334-1341. 2 - Includes heart failure with preserved ejection fraction, Shah et al, Journal of American College of Cardiology, 2019; hypertensive cardiomyopathy, Muiesan et al, Hypertension, 2004; Fabry disease, Orsborne et al, Journal of American College of Cardiology, 2022; and obstructive hypertrophic cardiomyopathy, Hegde et al, Journal of American College of Cardiology, 2021. 3 - Hughes DA, et al. J Med Genet, 2017;54:288–296; Migalastat; Solomon S, et al. Circulation, 2018. Patisiran; Saberi S, et al. Circulation, 2021;143:606–608. Mavacamten; Data on file. Increases in LVMi independently predict mortality in Friedreich Ataxia (FA) Natural history study showed a 19% higher risk of death per 10g/m2 (HR 1.19; 95% CI)1 MRI of individual with FA cardiomyopathy demonstrating significant hypertrophy. Concentric hypertrophy, with increased left ventricular mass and wall thickness, is a hallmark of FA cardiomyopathy1 In FA and many other cardiac diseases, elevated LVMi is not expected to significantly decrease without intervention,1,3 and abnormal LVMi is closely correlated with poor outcomes2 Reduction in LVMi may improve cardiac outcomes; key primary endpoint for pivotal trial in FA cardiomyopathy Disease Measure(3) LVMi or LVM Percent Change from Baseline in Placebo or Control Arm Fabry Disease LVMi at 18 months on ERT Amyloidosis (ATTR) LVM at 18 Months HCM LVMi at 30 Weeks No Significant Change in LVMi or LV Mass (LVM) Control Across Multiple Randomized Controlled Trials Note: Percent change in LVM / LVMi calculated based on change applied to baseline levels. -2 g/m2 (-2.2%) +0.6g (0.3%) -1.6 g/m2 (-1.7%) LX2006 Friedreich Ataxia


Slide 14

LX2006 clinical data show sustained or deepening improvements across cardiac measures of FA; LX2006 generally well tolerated 1- Participant 11 6-month visit not conducted due to hurricane; 3-month visit used for mean calculations. (2) Participant 10 not included in Hs-TNI chart due to scale. Values are +29% at 6M, +45% at 9M, +2,702% at 12M, +1,857% at 18M, +1,620% at 21M, and +1,458% at 24M as of most recent safety monitoring. Note: Data as of September 2026. Participants at 24-mo visit (n=6) -25% Participants at 12-mo visit (n=6) -23% Participants at 6-mo visit1 (n=6) -18% Cohorts 2 and 3 at 24-mo visit (n=3) -35% Cohorts 2 and 3 at 12-mo visit (n=3) -33% Cohorts 2 and 3 at 6-mo visit1 (n=3) -28% Majority of participants reach or remain in normal LVMi range at latest visit Durable LVMi improvement maintained out to three years following treatment Mean LVMi Change Among participants with abnormal baseline LVMi (key inclusion criteria for pivotal study; n=6): LVMi (g/m2) Cohort 1 (n=3) Cohort 2 (n=2) Cohort 3 (n=1) 16 of 17 participants have significantly reduced or stable troponin I, excluding participant with myocarditis2 Highly specific, blood-based marker of myocardial injury Improvement Cardiac MRI: LVMi (n=6; abnormal at baseline) Change from baseline (%) Improvement LX2006 generally well tolerated across 17 participants dosed with no Grade 3 treatment-related SAEs to date No clinically significant complement activation Minimal, transient LFT elevations No signs of frataxin over-expression observed in cardiac tissue One previously disclosed, possibly treatment-related Grade 2 event of asymptomatic myocarditis observed one year after dosing LX2006 generally well tolerated LX2006 Friedreich Ataxia % increase; absolute value remains normal Cohort 1 (n=6) Cohort 2 (n=6) Cohort 3 (n=4) Biomarkers: High-Sensitivity Troponin I (n=17)


Slide 15

Cardiac function improvement observed in individual with later stage cardiomyopathy Baseline LVEF: Normal Post therapy: No change Effect of LX2006 on Cardiac Function Majority of Participants (16/17) Baseline LVEF: Low (35%) Post Therapy: Significant improvements across all cardiac biomarkers One Participant (#13) with later stage cardiomyopathy Cardiac Improvements 24 months Post LX2006 Treatment in Participant with Low Baseline LVEF LX2006 Friedreich Ataxia Biomarker: High-Sensitivity Troponin I 86% reduction Cardiac MRI: LVMi 54% reduction Cardiac MRI: LVEF LVMi (g/m2) LVEF (%) hs troponin I (ng/L) Biomarker: NT-Pro-BNP 91% reduction NT-ProBNP (pg/mL) BL, Baseline; LVMi, Left ventricular mass index; LVEF, Left ventricular ejection fraction; MRI, Magnetic resonance imaging; NT-Pro-BNP, N-terminal pro-B-type natriuretic peptide. Note: Data as of September 2026.


Slide 16

Sustained and deepening neurological improvement observed with LX2006 at 36 months mFARS, Modified Friedreich Ataxia Rating Scale; PSM, propensity score matched. Note: Data as of September 2026; *Participant #3 missed the Month 24 visit; Month 21 data were used instead. 1. 16 patients treated with LX2006 in the Open Label study were matched to a control group of individuals in the Friedrich Ataxia Global Clinical Consortium UNIFIED Natural History Study of Friedrich’s Ataxia (UNIFAI) in a 3:1 ratio. While some patients did not have 2 years of follow up, this model is using every patient’s earlier visits to inform the rate-of-change estimate for mFARS (an annualized slope). Analysis performed by Christian Rumney in partnership with FARA. Mean Change from Baseline (95% CI) Mean change in mFARS: LX2006 Friedreich Ataxia Baseline 12 mo. 24 mo. 36 mo. Mean Change from Baseline (95% CI) Baseline 12 mo. 24 mo. Change in mFARS (Total): Open Label Cohort (n=16) vs. UNIFAI Matched Control (n=44)1 Statistically significant slope difference (p=0.008) -5.0 -2.5 0.0 2.5 mFARS validated clinical scale measures FA neurological progression; higher scores represent disease worsening Among all participants with 24 months of follow-up (n=11), treatment with LX2006 resulted in a mean improvement of 2.13 points per year, or 4.26 points over two years, on the mFARS scale compared to propensity-matched control N=16 N=16 N=12* N=7 Among a subset of participants with 36 months of follow-up (n=7), treatment with LX2006 resulted in further improvement, with a mean change of over 4 points relative to baseline


Slide 17

Finalized SUNRISE-FA 2 pivotal protocol and SAP for LX2006 Vg/kg, vector genomes per kilogram; LVMi, left ventricular mass index; cMRI, cardiac magnetic resonance imaging; mFARS, modified Friedreich Ataxia Rating Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire; Hs, high sensitivity. Study design: Open-label pivotal study with untreated control arm (no placebo or sham) Dose: 1.2x1012 vg/kg, one-time IV infusion Sample Size: 26 participants, 13 participants treated with LX2006 Key Eligibility Criteria: 16 years and older: Abnormal baseline LVMi, ≥2SD above normal mean 6 to <16 years: Abnormal baseline LV wall thickness, assessed via echocardiography. Pediatric cohorts assessed primarily for safety Primary Endpoint: LVMi, via cMRI at 6 months Statistical Analysis Plan: Pivotal arms stratified to balance baseline LVMi Study powered for 15% or greater LVMi change at 6 months Key Secondary Endpoints: mFARS, KCCQ, Hs-Troponin I, lateral wall thickness Confirmatory Evidence Strategy: Lexeo remains in ongoing discussions with the FDA regarding potential use of certain secondary endpoints at the 12-month time point in SUNRISE-FA 2 to support full approval Expect topline data in the second half of 2027 and a potential BLA filing in the first half of 2028 LX2006 Friedreich Ataxia


Slide 18

SUNRISE-FA 2 is supported by clinical evidence, robust study design and execution readiness 1 -Participant 11 6-month visit not conducted due to hurricane; 3-month visit used for 6 month mean calculation. Observed Phase I/II efficacy exceeds assumptions incorporated into the pivotal study design ~18% LVMi reduction observed at 6 months, with ~28% reduction in higher dose cohorts (2 & 3) in patients with abnormal baseline LVMi1 Effect exceeds both the 10% clinically meaningful benchmark and the 15% powering threshold for SUNRISE-FA 2 LVMi has not been shown to improve without intervention Phase I/II LVMi Reductions Exceeded the Threshold Used to Power SUNRISE-FA 2 >99% of simulated trials met or exceeded the 15% powering threshold, with most outcomes exceeding by a wide margin Stratification ensures balanced distribution of disease severity and aligns study population Monte Carlo simulations support study assumptions Study Design Maximizes Ability to Detect a Clinically Meaningful Treatment Effect Operational infrastructure is in place to support key milestones through topline data and potential registration First SUNRISE-FA 2 participant enrolled in June 2026 CLARITY-FA enrollment continues to advance and supports identification of eligible participants into pivotal study; 19 active sites across 8 countries Topline data expected in 2H 2027; potential BLA submission in 1H 2028 Execution Readiness With Clear Catalyst Path Phase I/II data exceeded pivotal-study assumptions, statistical simulations demonstrate a high likelihood of achieving the primary endpoint, and operational execution is already underway, providing multiple independent sources of confidence in SUNRISE-FA 2 LX2006 Friedreich Ataxia


Slide 19

FA patients are highly concentrated and readily identifiable​ Sources: Data on file. Katharina Buesch & Rongrong Zhang (2022) A systematic review of disease prevalence, health-related quality of life, and economic outcomes associated with Friedreich’s Ataxia, Current Medical Research and Opinion, 38:10, 1739-1749, DOI: 10.1080/03007995.2022.2112870. Addressable FA patients are concentrated within a small network of specialty centers, creating a clear and efficient path to patient identification, referral and treatment for LX2006 if approved Majority of FA patients are managed at a limited number of specialized treatment centers Most target patients are genetically confirmed and actively followed at academic institutions Established partnerships with leading FA patient advocacy organizations facilitate patient identification and community outreach Existing relationships with multidisciplinary FA care teams, including cardiologists managing FA-CM, support efficient patient identification, evaluation and treatment activation Patient Identification FA Patient Populations LX2006 Friedreich Ataxia


Slide 20

Strong path forward for LX2006 Phase I/II Results Exceed the Effect Size in LVMi Used to Power the Pivotal Study Clinical Results SUNRISE-FA 2 Initiated with First Patient Enrolled in June 2026 Clinical Development Building Internal Commercial Capabilities to Support Successful Launch Commercial Preparation Differentiated AAVrh.10 Capsid and Commercial-Ready CMC Supply Chain Manufacturing & Supply Next Steps Continued FDA engagement on confirmatory evidence strategy; update expected once finalized Topline data readout expected in second half of 2027 Potential BLA submission under accelerated approval pathway in first half of 2028 LX2006 Friedreich Ataxia


Slide 21

Earlier Stage Friedreich Ataxia Programs


Slide 22

Lexeo’s FA platform also includes four differentiated approaches to increasing or replacing frataxin for the treatment of FA Plan to prioritize investment on the opportunities with the strongest potential for clinical patient impact, regulatory success and shareholder value creation Program Therapeutic approach Stage Route Role in FA platform LX3010 (MTL-104) Oral combination designed to increase frataxin through complementary mechanisms Clinical Oral Potential complementary oral approach LX3030 (MTL-707) Third-generation benzamide HDAC inhibitor designed to increase production of endogenous frataxin Preclinical Oral Potential differentiated oral approach LX3050 (MTL-501) TfR1-targeted frataxin-replacement fusion protein Preclinical IV Potential tissue-directed protein replacement LX3070 (MTL-801) TfR1-targeted antisense oligonucleotide for FXN mRNA stabilization Discovery IV Potential CNS-directed RNA approach HDAC, histone deacetylase; FXN, frataxin; TfR1, transferrin receptor 1; mFARS, modified Friedreich Ataxia Rating Scale.


Slide 23

Program highlights: Differentiated oral approaches to increase frataxin Differentiated oral profile combining robust frataxin upregulation with CNS exposure LX3030 Third-generation oral small molecule (sub-500Da) designed to increase production of endogenous frataxin in the CNS Builds on prior scientific validation of the HDAC target class Designed to enhance frataxin upregulation and central nervous system exposure Preclinical studies demonstrated robust increases in frataxin Potential differentiated oral approach to addressing the neurological manifestations of FA Early functional and biological signals support the potential for a differentiated oral approach LX3010 Clinical-stage, oral combination designed to increase frataxin through complementary mechanisms Approximately six-point improvement in mFARS scores at 16 weeks Mean nine-fold increase in frataxin protein levels from baseline in muscle biopsies across 11 FA patients Convenient oral formulation designed with the needs of individuals with FA in mind Potential differentiated approach supported by both an early functional signal and evidence of increased FXN protein levels mFARS, modified Friedreich Ataxia Rating Scale; FA, Friedreich ataxia; CNS, central nervous system; HDAC, histone deacetylase.


Slide 24

Program highlights: Complementary approaches to restore frataxin Direct protein replacement diversifies the platform beyond approaches that rely on endogenous frataxin production LX3050 Preclinical recombinant human frataxin fused to a proprietary anti-TfR1 Fab, designed to directly replace deficient frataxin and increase delivery to the brain Directly replaces deficient frataxin rather than depending on increased endogenous production TfR1 brain shuttle supports delivery across the blood-brain barrier and into multiple disease-relevant tissues In vitro studies demonstrated dose-responsive improvements in measures of mitochondrial function CNS-directed RNA stabilization creates an additional path to increasing endogenous frataxin LX3070 Discovery-stage ASO Fab conjugate program designed to stabilize FXN mRNA and increase translation of endogenous frataxin protein Differentiated RNA mechanism designed to increase the body’s own production of frataxin Combines an RNA-targeted mechanism with a proprietary anti-TfR1 Fab In vitro studies demonstrated dose-responsive increases in frataxin Potential CNS-directed RNA approach that further diversifies Lexeo’s multimodal FA platform TfR1, transferrin receptor 1; ASO, antisense oligonucleotide; FXN, frataxin; CNS, central nervous system.


Slide 25

Lexeo’s research collaborations also support sequential dosing of CNS-targeted gene therapy Sponsored research agreement evaluating intra-cisternal administration of LX2006 following systemic dosing in large animal models. Sequential dosing Option agreement providing the opportunity to secure a license to a novel IV, BBB-crossing capsid. Blood Brain Barrier-Crossing Capsid Novel immune suppression strategies Option agreement providing the opportunity to secure an exclusive license to VTX-PID, an IgG-degrading enzyme. CNS, central nervous system; IgG, immunoglobulin G.


Slide 26

Unlocking the full spectrum of FA LX2006 has the potential to serve as the cardiac foundation of a broader multimodal FA platform addressing both cardiac and neurological disease No cardiomyopathy Neuro-predominant disease Mild CM Diagnosed cardiac involvement Moderate CM Moderate cardiac disease Advanced CM Greater cardiac disease burden Potential disease-modifying gene therapy for FA cardiomyopathy LX2006 FA-CM Opportunity Potential label-broadening opportunity for LX2006 pending additional mFARS data Neurological burden can span the full continuum Cardiomyopathy Spectrum Future Multimodal Platform Potential Complementary modalities with potential standalone, sequential or combined use with LX2006 Small molecules Protein replacement RNA-based Neuro-targeted collaborations Gene therapy Potential reach regardless of cardiomyopathy status or stage FA, Friedreich ataxia; FA-CM, Friedreich ataxia cardiomyopathy; CM, cardiomyopathy; mFARS, modified Friedreich Ataxia Rating Scale.


Slide 27

Plakophilin 2 Arrhythmogenic Cardiomyopathy Gene Therapy LX2020 27


Slide 28

PKP2 arrhythmogenic cardiomyopathy is a progressive genetic heart disease with significant unmet need PKP2-ACM has a clearly defined genetic cause alongside progressive, potentially life-threatening cardiac consequences, with no disease-modifying therapy today Disease overview Rare, genetic cardiac disease Caused by loss of function mutations in the PKP2 gene Progressive replacement of cardiac muscle with fatty fibrotic tissue1,2 ~60,000 affected in the U.S. Cardiac impact Disrupted electrical signaling → ventricular arrhythmias and sudden cardiac death (SCD)1,2 ~23% of individuals present with SCD3,4 Progressive disease associated with reduced quality of life3,4 The unmet need No therapies address the underlying genetic cause of ACM Current management focuses on symptom control and SCD prevention (e.g., ICDs)2,3 Disease progression continues despite intervention ACM, arrhythmogenic cardiomyopathy; ICD, implantable cardioverter defibrillator; PKP2, Plakophilin-2; SCD, sudden cardiac death. Sources: (1) Cedars-Sinai, 2023, Accessed from: https://www.cedars-sinai.org/health-library/diseases-and-conditions/a/arrhythmogenic-right-ventricular-dysplasia.html. (2) Corrado, D., et al. Cir Res, 2017;121:784-802; (3) Dalal, D. et al. Circulation, 2005;112:3823-3832. (4) Day, S.M., Circ: Cardiovasc Genet, 2012;5(1):2-4.


Slide 29

Significant commercial potential for LX2020 given unmet need and global patient population 60K Patients in the U.S. >$4-6B Total addressable market opportunity Larger-rare, diagnosed population Significant commercial upside at peak Trial ready Broad patient pool expected to support rapid recruitment Manufacturing scale Differentiated Lexeo process will enable rapid and cost-efficient supply Global prevalence Pivotal study feasible across US, EU, Asia and other geographies LX2020 PKP2-ACM


Slide 30

*AADs, aanti-arrhythmia drugs; ACM, arrhythmogenic cardiomyopathy. Sources: (1) Daimee et al 2021 n=166. (2) Gaine et al. 2025, N=83. Current therapies may help manage arrhythmias, but limitations in durability, efficacy & tolerability leave a significant unmet need 50% VT recurrence reported within 5 years after a single procedure1 Severe arrhythmia recurrence common after ablation VT recurrence after 1YR VT recurrence after 5YR Single procedure Repeat procedures Existing therapies may reduce arrhythmia burden but overall efficacy in PKP2-ACM may be limited and certain AADs present tolerability concerns Safety and tolerability may limit long-term use of AADs* ~39% of those with PKP2-ACM experienced NSVT prior to treatment, and ~27% continued to experience NSVT after treatment (31% relative reduction) Limited reduction in NSVT burden with available drugs 50 40 30 20 10 0 Baseline (N=83) On antiarrhythmic therapy (N=83) 38.6% 26.5% 31% relative reduction (not statistically significant) p = 0.096 Patients with NSVT (%) Effect of antiarrhythmic therapy flecainide on NSVT in PKP2-ACM population Largest available dataset2 Flecainide may increase the risk of proarrhythmia and conduction abnormalities Amiodarone is associated with pulmonary, thyroid, hepatic, ocular, and dermatologic toxicities, particularly with long-term use Chronic use may require ongoing safety monitoring and treatment modification Existing therapies are not approved for ACM and are used off label Importantly, no existing therapies address the underlying genetic cause of ACM; Disease progression continues despite intervention


Slide 31

LX2020 delivers a full-length PKP2 gene to cardiomyocytes, restoring the desmosome PKP2 cDNA (full length gene) Rabbit β-globin polyA AAVrh.10hPKP2 LX2020 construct: Cardiac-specific promoter Promoter PKP2 gene Poly-A PKP2-ACM: LX2020 mechanism: PKP2 expression is expected to restore the balance of desmosomal proteins by scaffolding adjacent cell-cell junctional proteins The restoration of PKP2 may lead to improvement in cardiac electrical and mechanical function as well as inhibit further structural damage Absence of PKP2 results in impairment of cardiac desmosomes, leading to abnormal cardiac rhythms (arrhythmias) and onset of cardiac dysfunction Desmosomal complex AAVrh.10 Desmin Desmoplakin DES DES Plakoglobin PKP2 Desmoglein-2 Desmocollin-2 DES DES Desmosomal complex Absent PKP2 Desmoglein-2 Desmocollin-2 Desmin Desmoplakin Plakoglobin LX2020 PKP2-ACM AAV, Adeno-Associated Virus; PKP2, Plakophilin-2; cDNA, Copy DNA; Poly-A, Poly Adenosine, ACM; arrhythmogenic cardiomyopathy.


Slide 32

LX2020 is being evaluated in an ongoing Phase I/II study: HEROIC-PKP2 2 Key Inclusion Criteria Adults (18-65 years) Diagnosis of ACM with documented PKP2 mutation Existing ICD that is MRI compatible Minimum threshold of PVCs/24-hr Neutralizing anti-AAVrh.10 titer cutoff 1 Study Design & Objective Design: 52-week open-label study with a 4-year long term follow up Objective: To assess the safety and efficacy of LX2020 in individuals with PKP2-ACM High dose (n=7): 6.0x1013 vg/kg Low dose (n=3): 2.0x1013 vg/kg 52-Week Fully Enrolled 3 Key Measurements Change in symptoms (NYHA Class and PROs) Ventricular arrhythmias and associated measures (PVC, NSVT, VT, QRS) Cardiac structure & function (EF, EDV, ESV, RV strain) Vector Transduction & Expression ACM, arrhythmogenic cardiomyopathy; ICD, implantable cardioverter defibrillator; PVC, premature ventricular contraction; NSVT, non-sustained ventricular tachycardia; VT, ventricular tachycardia; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; RV, right ventricular; NYHA, New York Heart Association; PROs, patient reported outcomes. Note: LX2020 is administered systemically; participants receive immune suppression with prednisone and sirolimus on the day prior to treatment through ~14 weeks following LX2020 dosing. Lexeo has also sponsored SNAPSHOT, a retrospective EMR review and prospective observational natural history study (n=15). LX2020 PKP2-ACM


Slide 33

Interim LX2020 data demonstrate clinically meaningful reductions in severe arrhythmia burden Sources: (1) Gasperetti A, et al. JAMA Cardiol. 2022;7(4):378-385. Note: Data as of October 15, 2026. Participant 3 (low dose) declined 18-month follow up visit but is expected for 24-month follow up. NSVT, non-sustained ventricular tachycardia; PVC, premature ventricular contraction; LFT, liver function tests; SAE, serious adverse event; ACM, arrhythmogenic cardiomyopathy. NSVT: NSVT / 7d ≥7 NSVT / 7d n=3 n=7 n=6 n=2 n=2 n=1 LX2020 generally well tolerated across 10 participants dosed No clinically significant complement activation No study discontinuations Previously disclosed LFT elevations observed in high-dose cohorts were successfully managed per protocol with no hospitalizations or complications One previously disclosed Grade 3 SAE of sustained ventricular tachycardia (VT), consistent with the natural course of PKP2-ACM LX2020 generally well tolerated Mean NSVT Change % Participants with Significant NSVT Burden (at least 7 NSVT / 7d; High-dose Cohorts) NSVT / 7d NSVT Change Per Participant Deepening NSVT reduction over time with 80% mean reduction at latest visit in high-dose cohorts (n=7); 53% increase in NSVT at 12 months in SNAPSHOT natural history study (n=15) 5 of 6 participants experienced <1 NSVT per day at 12 months, a clinically relevant threshold to predict risk of future sustained and life-threatening arrhythmias NSVT improved in 6/7 participants at latest visit relative to baseline; in most participants, NSVT reductions were substantial Mean PVC Change: n=3 n=7 n=6 n=2 n=2 n=1 LX2020 PKP2-ACM n=7 n=6 n=2 n=15


Slide 34

Strong path forward for LX2020 Meaningful Clinical Activity LX2020 continues to demonstrate improvements across multiple measures of disease burden and patient experience Increasing Confidence in Dataset Additional follow-up strengthens the durability, consistency, and overall benefit-risk profile of LX2020 Clear Path Forward FDA open to guideline-defined NSVT1 as a primary surrogate endpoint to support potential accelerated approval of LX2020 Interim HEROIC-PKP2 data continue to support LX2020's potential as the first disease-modifying therapy for PKP2-ACM 1 2 3 Sources: Al-Khatib SM, et al. Circulation. 2018;138:e272–e391. Carrick RT, et al. Circ Arrhythm Electrophysiol. 2022;15:e011207. (1) NSVT defined in guidelines as hemodynamically stable ventricular tachycardia at a rate of >100 beats per minute, lasting three or more beats and less than 30 seconds. LX2020 PKP2-ACM


Slide 35

Preclinical Cardiac Programs 35


Slide 36

Lexeo is also advancing two preclinical cardiac gene therapy programs +Research collaboration with Johnson & Johnson exploring novel routes of administration for cardiac AAV gene therapy to maximize safety and efficacy Significant unmet need characterized by extensive fibrosis, high arrhythmic risk and substantial heart failure burden 30-50% mortality within 5 years of diagnosis for dilated phenotype ~35K patients in the U.S. IND-enabling studies ongoing DSP (Desmoplakin) Cardiomyopathy LX2021 LX2022 TNNI3 variants compose 3-5% of all HCM cases, causing cardiomyopathy, clinical heart failure and shortened lifespan Non-obstructive phenotype, often with preserved ejection fraction; myosin inhibitors not effective ~25K patients in the U.S. Hypertrophic Cardiomyopathy


Slide 37

Thank you

Filing Exhibits & Attachments

4 documents

Keep reading